NRC Health (National Research Corporation) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2004. National Research Corporation (NRC Health) provides survey-based performance measurement, analysis, and tracking services to the healthcare industry. The company utilizes methodologies such as direct mail, telephone surveys, and focus groups to help healthcare providers and payers measure patient care outcomes and compliance with regulatory standards.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 |
|---|---|---|
| Revenues | $9,320,349 | $23,252,991 |
| Net Income | $1,716,361 | $3,630,033 |
| Operating Income | $2,783,498 | $5,994,202 |
| Operating Margin | 29.8% | 25.8% |
| Net Income Per Share (Diluted) | $0.24 | $0.50 |
| Cash and Cash Equivalents | $2,543,435 | $2,543,435 (Balance Sheet) |
| Working Capital | $17,571,156 | $17,571,156 (Balance Sheet) |
| Total Debt (Notes Payable) | $4,937,088 | $4,937,088 (Balance Sheet) |
| Net Cash from Operating Activities | N/A | $5,584,217 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 16.6% for the quarter and 15.2% for the nine-month period compared to the prior year. Growth was driven by new client acquisitions and expanded scope with existing clients.
- Expense Management: Direct expenses increased 9.9% (quarter) and 9.8% (nine months) but decreased as a percentage of revenue (44.8% and 43.8% respectively) due to margin expansion. Selling, general, and administrative (SG&A) expenses rose 16.6% (quarter) and 27.3% (nine months) due to increased sales/marketing efforts and mid-management expansion.
- Cash Flow: Net cash provided by operating activities decreased to $5.6 million for the nine months ended September 30, 2004, from $7.5 million in the prior year. This decline was primarily due to changes in working capital, specifically decreases in billings in excess of revenues earned and increases in accounts receivable.
- Stock Repurchases: The company significantly increased cash used in financing activities ($2.7 million) compared to the prior year ($20,000), primarily due to the purchase of treasury stock under an authorized program.
Guidance, Outlook, and Risks
- Outlook: Management expects direct expenses to remain in line with an annual goal of 43% to 45% of revenue. SG&A expenses are expected to align with an annual goal of 23% to 25% of revenue. Depreciation and amortization are expected to remain between 5.5% and 6.5% of revenue.
- Deferred Revenue: The company holds $3.4 million in deferred revenue (billings in excess of revenues earned) and $1.3 million in unbilled revenue, which are expected to be recognized within 12 months.
- Accounting Changes: The company adopted EITF 03-1 regarding "other-than-temporary impairment" of investments. Management does not expect this to have a material effect on financial statements.
- Risks: The filing notes that trends illustrated in the financial data may not be indicative of future results. The company relies on cash flow from operations for liquidity.
Investor Verification Checklist
- Verify the sustainability of the 16.6% revenue growth rate and the retention of new clients.
- Monitor the trend in "Billings in excess of revenues earned," which decreased by $1.0 million in the nine-month period, impacting operating cash flow.
- Review the impact of the stock repurchase program on future liquidity and capital allocation.
- Confirm the effective tax rate stability, which rose slightly to 38.6% for the quarter due to state tax differences.
- Assess the company's ability to maintain direct expense margins within the 43-45% target range as volume increases.